Rittenmeyer Ronald A
Known title: Executive ChairmanCIK: 0001210018
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
IQVIA Expands Veeva Partnership and Raises Price Targets. IQVIA announced an expanded partnership with Veeva Systems to use clinical operations software across its development studies. This move coincides with reports of an improving demand environment and high win rates. Stifel recently raised its price target for the stock to $303, reflecting confidence in the company's backlog and operational updates.
Transaction History
| THC | ▲ Buy | Option Exercise | 32,702 | — | 9/30/2022 | View on chart |
| THC | ▼ Sell | Tax Withholding | 12,869 | $664K | 9/30/2022 | View on chart |
| THC | ▲ Buy | Option Exercise | 23,652 | — | 9/30/2022 | View on chart |
| THC | ▼ Sell | Tax Withholding | 9,308 | $480K | 9/30/2022 | View on chart |
| THC | ▲ Buy | Option Exercise | 4,883 | — | 9/30/2022 | View on chart |
| THC | ▼ Sell | Tax Withholding | 1,922 | $99K | 9/30/2022 | View on chart |
| THC | ▲ Buy | Option Exercise | 23,652 | — | 6/30/2022 | View on chart |
| THC | ▼ Sell | Tax Withholding | 9,308 | $489K | 6/30/2022 | View on chart |
| THC | ▲ Buy | Option Exercise | 32,701 | — | 6/30/2022 | View on chart |
| THC | ▼ Sell | Tax Withholding | 12,868 | $676K | 6/30/2022 | View on chart |
| THC | ▼ Sell | Tax Withholding | 1,922 | $101K | 6/30/2022 | View on chart |
| THC | ▲ Buy | Option Exercise | 4,883 | — | 6/30/2022 | View on chart |
| IQV | ▲ Buy | Grant | 995 | $0 | 5/11/2022 | View on chart |
| THC | ▲ Buy | Option Exercise | 23,652 | — | 3/31/2022 | View on chart |
| THC | ▼ Sell | Tax Withholding | 9,308 | $800K | 3/31/2022 | View on chart |
| THC | ▲ Buy | Option Exercise | 32,701 | — | 3/31/2022 | View on chart |
| THC | ▼ Sell | Tax Withholding | 12,868 | $1.1M | 3/31/2022 | View on chart |
| THC | ▼ Sell | Open Market | 190,149 | $17.2M | 3/3/2022 | View on chart |
| THC | ▼ Sell | Open Market | 59,851 | $5.4M | 3/2/2022 | View on chart |
| THC | ▼ Sell | Tax Withholding | 12,868 | $1.1M | 12/31/2021 | View on chart |
| THC | ▲ Buy | Option Exercise | 23,652 | — | 12/31/2021 | View on chart |
| THC | ▼ Sell | Tax Withholding | 7,561 | $618K | 12/31/2021 | View on chart |
| THC | ▲ Buy | Option Exercise | 32,701 | — | 12/31/2021 | View on chart |
| THC | ▼ Sell | Open Market | 5,799 | $452K | 12/16/2021 | View on chart |
| THC | ▼ Sell | Open Market | 6,090 | $463K | 12/10/2021 | View on chart |
| THC | ▼ Sell | Open Market | 65,897 | $5.0M | 12/8/2021 | View on chart |
| THC | ▼ Sell | Open Market | 11,308 | $860K | 12/7/2021 | View on chart |
| THC | ▼ Sell | Open Market | 152 | $12K | 11/24/2021 | View on chart |
| THC | ▼ Sell | Open Market | 21,984 | $1.7M | 11/23/2021 | View on chart |
| THC | ▼ Sell | Open Market | 29,520 | $2.3M | 11/22/2021 | View on chart |
| THC | ▼ Sell | Open Market | 95 | $8K | 11/19/2021 | View on chart |
| THC | ▼ Sell | Open Market | 49,905 | $3.9M | 11/18/2021 | View on chart |
| THC | ▼ Sell | Open Market | 19,353 | $1.6M | 11/16/2021 | View on chart |
| THC | ▼ Sell | Open Market | 29,974 | $2.4M | 11/15/2021 | View on chart |
| THC | ▲ Buy | Option Exercise | 23,652 | — | 9/30/2021 | View on chart |
| THC | ▼ Sell | Tax Withholding | 9,308 | $618K | 9/30/2021 | View on chart |
| THC | ▲ Buy | Option Exercise | 32,701 | — | 9/30/2021 | View on chart |
| THC | ▼ Sell | Tax Withholding | 12,868 | $855K | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets
Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets. Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.